DNDN Related Hot FDA News
-
Committee Recommends J&J's (JNJ) ZYTIGA Study Be Unblinded Amid Better Survival Data
-
Dendreon (DNDN) Announces CMS Will Now Cover Costs Related to Administration of PROVENGE
-
Dendreon (DNDN) Discloses Restructuring Efforts: Cutting 500 Jobs, COO Leaving; Sees PROVENGE Sales of $22M in Aug.
-
CMS says Dendreon's (DNDN) Provenge Should be Covered (LINK)
-
Dendreon's (DNDN) Provenge Should Be Covered by Medicare, Agency Says
-
Dendreon (DNDN) Updates on PROVENGE Strategy
Back to DNDN Stock Lookup
